PFE and JNJ Related Headlines
Go Back- Trump to announce prescription drug price agreements
- Wells Fargo sees 'room to run' for Johnson & Johnson, highlights pharma upside
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
- CDC Panel Votes Against Requiring Prescriptions For Covid Shots - Bloomberg
- CDC Panel Votes To End Universal Recommendation For Covid Shots - Bloomberg
- Top 20 Companies Recognized in Labrador Transparency’s 2025 U.S. Transparency Awards
- Trump demands pharma CEOs lower drug prices within 60 days
- Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
- Lawmakers push to ban direct-to-consumer drug advertising, WSJ reports
